Inhibrx Biosciences (INBX) stock: insider trades, news & valuation
Health Care · Strong buyingShare price and insider trades
Inhibrx Biosciences insider trading at a glance (Oct 9, 2026): in the past 12 months, 3 insiders bought $5.5M and 2 sold $11.6M of INBX stock on the open market, including a cluster buy that began Sep 8, 2026.
Get emailed when insiders cluster-buy stocks like INBX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
INBX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $5.5M | 14 | $279K | 5 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | — | 0 | $11.3M | 3 |
Valuation, profit and volume
Pick score 59/100Summary
Over the past 12 months, 3 Inhibrx Biosciences, Inc. insiders reported open-market purchases totaling $5.5M, while 2 insiders reported sales totaling $11.6M. The most recent cluster buy began on Sep 8, 2026, when 3 insiders bought a combined $4.0M. 0 of 8 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
INBX stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 28SEC | Mark LappeCEO | Buy | 3,324733,872 held (+0%) | $98.87 | $329K | -3.9% | — |
| Sep 28SEC | Mark LappeCEO | Buy | 3,000740,548 held (+0%) | $101.70 | $305K | -6.6% | — |
| Sep 28SEC | Mark LappeCEO | Buy | 2,176736,048 held (+0%) | $99.60 | $217K | -4.6% | — |
| Sep 28SEC | Mark LappeCEO | Buy | 1,500737,548 held (+0%) | $98.88 | $148K | -3.9% | — |
| Sep 23SEC | Jon Faiz KayyemDirector | Buy | 5,000434,360 held (+1%) | $100.00 | $500K | -5.0% | — |
| Sep 17SEC | Jon Faiz KayyemDirector | Buy | 5,000429,360 held (+1%) | $100.00 | $500K | -5.0% | — |
| Sep 15SEC | Kimberly ManhardDirector | Sell | 5008,500 held (−6%) | $111.78 | $56K | -15.0% | — |
| Sep 15SEC | Kimberly ManhardDirector | Sell | 5008,000 held (−6%) | $110.26 | $55K | -13.8% | — |
| Sep 15SEC | Kimberly ManhardDirector | Sell | 5007,500 held (−6%) | $105.05 | $53K | -9.6% | — |
| Sep 10SEC | Kimberly ManhardDirector | Sell | 5009,000 held (−5%) | $115.80 | $58K | -18.0% | — |
| Sep 10SEC | Kimberly ManhardDirector | Sell | 5009,500 held (−5%) | $115.14 | $58K | -17.5% | — |
| Sep 8SEC | Mark LappeCEO | Buy | 9,681730,548 held (+1%) | $112.28 | $1.1M | -15.4% | — |
| Sep 8SEC | Mark LappeCEO | Buy | 6,605718,048 held (+1%) | $100.64 | $665K | -5.6% | — |
| Sep 8SEC | Mark LappeCEO | Buy | 5,895711,443 held (+1%) | $99.29 | $585K | -4.3% | — |
| Sep 8SEC | Jon Faiz KayyemDirector | Buy | 5,000424,360 held (+1%) | $113.52 | $568K | -16.3% | — |
| Sep 8SEC | Douglas ForsythDirector | Buy | 2,500227,064 held (+1%) | $114.65 | $287K | -17.1% | — |
| Sep 8SEC | Mark LappeCEO | Buy | 1,219720,867 held (+0%) | $111.88 | $136K | -15.1% | — |
| Sep 8SEC | Mark LappeCEO | Buy | 1,100719,148 held (+0%) | $107.12 | $118K | -11.3% | — |
| Sep 8SEC | Mark LappeCEO | Buy | 500719,648 held (+0%) | $108.24 | $54K | -12.2% | — |
| Oct 9SEC | Viking Global Opportunities Parent Gp Llc10% Owner | Sell | 308,6431,267,823 held (−20%) | $32.25 | $10.0M | +194.6% | — |
| Oct 9SEC | Viking Global Opportunities Parent Gp Llc10% Owner | Sell | 25,042102,864 held (−20%) | $32.25 | $808K | +194.6% | — |
| Oct 9SEC | Viking Global Opportunities Parent Gp Llc10% Owner | Sell | 16,31567,018 held (−20%) | $32.25 | $526K | +194.6% | — |
Insiders at Inhibrx Biosciences, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Viking Global Opportunities Parent Gp Llc10% Owner | — | $11.3M | Oct 9, 2025 | — |
| Mark LappeCEO | $3.6M | — | Sep 28, 2026 | — |
| Jon Faiz KayyemDirector | $1.6M | — | Sep 23, 2026 | — |
| Douglas ForsythDirector | $287K | — | Sep 8, 2026 | — |
| Kimberly ManhardDirector | — | $279K | Sep 15, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
INBX stock: common questions
Are Inhibrx Biosciences, Inc. insiders buying INBX stock?
In the past 12 months, 3 insiders reported open-market purchases of INBX worth $5.5M. The latest was CEO Mark Lappe bought $329K of INBX at $98.87.
Are Inhibrx Biosciences, Inc. insiders selling INBX stock?
2 insiders reported sales worth $11.6M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is INBX's 52-week range?
Over the past year INBX has traded between $28.36 and $141.84. It last closed at $95.01 on Oct 9, 2026.